Transcriptomics analysis identified ezrin as a potential druggable target in cervical and gastric cancer cells
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study shows that high ezrin (EZR) expression in cervical and gastric cancers correlates with poor outcomes. Inhibiting ezrin with NSC305787 reduced cancer cell growth and promoted cell death, suggesting ezrin as a potential therapeutic target.
Area Of Science
- Oncology
- Molecular Biology
- Genomics
Background
- Ezrin (EZR) is a protein highly expressed in cancer, linking the cytoskeleton to the cell membrane and influencing oncogenesis.
- EZR plays a role in signal transduction pathways critical for cancer progression.
- Pharmacological inhibition of ezrin shows potential antineoplastic effects.
Purpose Of The Study
- To investigate EZR mRNA levels across 32 cancer types using TCGA data.
- To evaluate the association of EZR transcript levels with clinical outcomes in cervical squamous cell carcinoma and stomach adenocarcinoma.
- To assess the anti-cancer effects of the ezrin inhibitor NSC305787 in cellular models.
Main Methods
- Pan-cancer analysis of TCGA data for EZR mRNA expression.
- Correlation analysis of EZR levels with clinical outcomes and gene expression profiles.
- In vitro treatment of cervical and gastric cancer cell lines with NSC305787.
- Cellular and molecular assays to evaluate drug efficacy, including cell viability, clonal growth, apoptosis, and DNA damage markers.
Main Results
- EZR mRNA is highly expressed in cervical squamous cell carcinoma and stomach adenocarcinoma, associated with relevant molecular processes.
- Treatment with NSC305787 significantly reduced cell viability and clonal growth in cellular models of cervical and gastric cancer (p < 0.05).
- Pharmacological ezrin inhibition induced markers of cell death and DNA damage, while promoting apoptosis-related genes and inhibiting survival/proliferation genes.
Conclusions
- Ezrin (EZR) is a promising molecular target for novel anti-cancer therapies.
- Targeting ezrin may be a viable strategy for treating cervical and gastric carcinomas.
- Further research into anti-EZR therapies is warranted based on these findings.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...